Tus%252525252525252520qd

# Tus-QD ## Overview Tus-QD is a prescription-strength antitussive/decongestant/antihistamine combination typically formulated as a sustained-release (SR) liquid or tablet. The specific formulation usually contains **Chlorpheniramine (antihistamine), Phenylephrine (decongestant), and Dextromethorphan (antitussive)** designed for once-daily or twice-daily dosing depending on the specific NDC/brand variation. *Note: Always verify the specific active ingredients in the product dispensing, as "Tus-QD" is a trade name often used for generic reformulations.* ## Primary Indications Symptomatic relief of cough, nasal congestion, and upper respiratory symptoms associated with common cold, allergic rhinitis, or sinusitis. ## Adult Dosing * **Standard:** 10 mL (or 1 tablet) orally every 12 to 24 hours depending on specific product labeling. * **Maximum:** Follow specific labeling (typically 10-20 mL per 24 hours). Do not exceed recommended frequency due to the risk of additive stimulant/anticholinergic side effects. ## Pediatric Dosing * **Children < 6 years:** Not recommended. * **Children 6–12 years:** 5 mL every 12 to 24 hours as directed by labeling. * **Adolescents > 12 years:** Same as adult dosing. * *Note: Pediatric dosing is highly specific to the manufacturer's formulation. Confirm weight-based appropriateness.* ## Dose Adjustments * **Renal/Hepatic Impairment:** Exercise caution; no specific standardized guidelines exist for this combination, but assess baseline organ function as components (specifically antihistamines) may accumulate. * **Geriatric:** Start at the lower end of the dosing range; increased risk of urinary retention, confusion, and falls due to anticholinergic effects. ## Contraindications * Hypersensitivity to any component. * Concomitant use of MAO Inhibitors (within 14 days). * Severe hypertension or severe coronary artery disease (due to phenylephrine). * Narrow-angle glaucoma, urinary retention, or symptomatic prostatic hypertrophy. ## Adverse Effects * **Common:** Drowsiness, dizziness, dry mouth, blurred vision, thickened bronchial secretions. * **Serious:** Hypertension, tachycardia, urinary retention, paradoxical CNS excitation (especially in children/elderly). ## Key Drug Interactions * **MAOIs:** Risk of hypertensive crisis. * **CNS Depressants/Alcohol:** Additive sedative effects. * **Antihypertensives:** Decongestants (phenylephrine) may decrease the efficacy of antihypertensive therapy. * **SSRI/SNRIs:** Potential risk for serotonin syndrome when combined with dextromethorphan. ## Monitoring * Monitor blood pressure periodically if used long-term (rare for this indication). * Assess for sedation levels and ability to drive/operate machinery. * Monitor for urinary retention or signs of anticholinergic toxicity. ## Clinical Pearls * **Anticholinergic Burden:** Significant in elderly patients; use with caution. * **Dextromethorphan Misuse:** Be aware of potential for abuse of high-dose dextromethorphan. * **Hydration:** Encourage increased fluid intake to assist in thinning bronchial secretions. * **Label Confusion:** Always check the specific ingredient ratio on the bottle, as generic brands labeled "Qd" formulations vary by manufacturer content. *** **Educational Disclaimer:** This information is provided for educational purposes only. Drug information, dosing, and contraindications change frequently. Always consult the most current official prescribing information (package insert), clinical decision support systems (e.g., Lexicomp, UpToDate), or a pharmacist before prescribing or administering medication.